(Q35696163)

9 August 2017

1 reference

title

Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia (English)

1 reference

9 August 2017

1 reference

Robert S Rosenson

1

1 reference

9 August 2017

1 November 2003

1 reference

Expert Review of Cardiovascular Therapy

9 August 2017

1 reference

9 August 2017

1

1 reference

9 August 2017

4

1 reference

9 August 2017

495-505

1 reference

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population

9 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Optimizing the pharmacology of statins: characteristics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Effect of itraconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

The effect of erythromycin on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

The effect of fluconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.4.495

21 January 2018

Identifiers

DOI

10.1586/14779072.1.4.495

1 reference

9 August 2017

1 reference

PubMed ID

15030249